Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of N-Methyl Pyrrolidine (Nmp). The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N-Methylpiperidine SCHEMBL3145445 | 0.97 | CYP1A2 (0.48) | CYP1A2TDP1FFAR3LCKFYN | |
| N-Methyl Pyrrolidine (Nmp) SCHEMBL5425502 | 0.97 | CYP1A2 (0.48) | CYP1A2TDP1FFAR3LCKFYN | |
| N-Methylpiperidine SCHEMBL1050930 | 0.94 | CYP1A2 (0.46) | CYP1A2TDP1FFAR3LCKFYN | |
| N-Methylpiperidine SCHEMBL11210549 | 0.88 | CYP1A2 (0.50) | CYP1A2TDP1HTTLMNAPAOX | |
| N-Methyl Pyrrolidine (Nmp) SCHEMBL9368873 | 0.88 | KDM4E (0.44) | CYP1A2TDP1HTTLMNAALDH1A1 | |
| N-Methyl Pyrrolidine (Nmp) SCHEMBL28432798 | 0.85 | CYP1A2 (0.42) | CYP1A2TDP1HTTLMNAPAOX | |
| N-Methylpiperidine SCHEMBL3849400 | 0.85 | ALDH1A1 (0.47) | CYP1A2TDP1HTTLMNAALDH1A1 | |
| N-Methylpiperidine SCHEMBL27874745 | 0.82 | CYP1A2 (0.46) | CYP1A2TDP1HTTLMNAPAOX | |
| N-Methylpiperidine SCHEMBL29238591 | 0.82 | CYP1A2 (0.41) | CYP1A2TDP1HTTLMNAALDH1A1 | |
| N-Methyl Pyrrolidine (Nmp) SCHEMBL5454178 | 0.82 | PAOX (0.40) | CYP1A2TDP1LMNAPAOXALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2265617-B1 | SOLVENTS | BIONIQS LTD (GB) | 2014-07-02 | — | — | EP | claimed |
| EP-2265617-A1 | SOLVENTS | Bioniqs Limited (GB) | 2010-12-29 | — | — | EP | claimed |
| WO-2009034329-A1 | SOLVENTS | BIONIQS LIMITED (GB) | 2009-03-19 | — | — | WO | claimed |
| US-6361940-B1 | IMMOBILIZATION; GENETIC ENGINEERING | QIAGEN GENOMICS, INC. | 2002-03-26 | — | — | US | claimed |
| US-20250242275-A1 | APPARATUS AND METHOD FOR PROCESSING A BIOMASS MATERIAL | BUSS-SMS-CANZLER GMBH (DE) | 2025-07-31 | — | — | US | disclosed |
| US-20250145889-A1 | METHOD FOR PROCESSING A BIOMASS MATERIAL | PROIONIC GMBH (AT) | 2025-05-08 | — | — | US | disclosed |
| US-20250066860-A1 | METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2025-02-27 | — | — | US | disclosed |
| CN-111868260-B | Methods and materials for assessing and treating cancer | 约翰斯霍普金斯大学 | 2025-02-21 | — | — | CN | disclosed |
| US-12195803-B2 | Methods and materials for assessing and treating cancer | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-01-14 | — | — | US | disclosed |
| US-20240393290-A1 | ELECTROCHEMICAL GAS SENSOR AND ELECTROLYTE FOR AN ELECTROCHEMICAL GAS SENSOR | Dräger Safety AG & Co. KGaA (DE) | 2024-11-28 | — | — | US | disclosed |
| CN-118804981-A | Method for processing biomass material | 普罗奥尼克股份有限公司 | 2024-10-18 | — | — | CN | disclosed |
| EP-4377467-A2 | METHOD FOR PROCESSING A BIOMASS MATERIAL | proionic GmbH (AT) | 2024-06-05 | — | — | EP | disclosed |
| US-6361940-B1 | IMMOBILIZATION; GENETIC ENGINEERING | QIAGEN GENOMICS, INC. | 2002-03-26 | — | — | US | disclosed |
| US-6312893-B1 | GENERATING TAGGED NUCLEIC ACID FRAGMENTS WHICH ARE COMPLEMENTARY TO SELECTED TARGET NUCLEIC ACID MOLECULE; SEPARATION OF TAGGED FRAGMENTS; CLEAVING THE TAGS; DETECTING TAGS BY NON-FLUORESCENT SPECTROMETRY OR POTENTIOMETRY | QIAGEN GENOMICS, INC. | 2001-11-06 | — | — | US | disclosed |
| EP-0990047-A2 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID MOLECULES UTILIZING SIZING TECHNIQUES | Rapigene, Inc. (US) | 2000-04-05 | — | — | EP | disclosed |
| EP-0958378-A2 | COMPOSITIONS AND METHODS FOR ENHANCING HYBRIDIZATION SPECIFICITY | Rapigene, Inc. (US) | 1999-11-24 | — | — | EP | disclosed |
| EP-0952228-A2 | Compositions and methods for enhancing hybridization specificity | Rapigene, Inc. (US) | 1999-10-27 | — | — | EP | disclosed |
| WO-1999005319-A9 | METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY | RAPIGENE INC (US) | 1999-06-17 | — | — | WO | disclosed |
| WO-1999005319-A2 | METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY | RAPIGENE, INC. (US) | 1999-02-04 | — | — | WO | disclosed |
| WO-1998013527-A2 | COMPOSITIONS AND METHODS FOR ENHANCING HYBRIDIZATION SPECIFICITY | RAPIGENE, INC. (US) | 1998-04-02 | — | — | WO | disclosed |